Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

(2015) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

(2015) Andiliy Lai et al.   JOURNAL OF MEDICINAL CHEMISTRY

New Global Survey Shows an Increasing Cancer Burden

(2014) David Carter   AMERICAN JOURNAL OF NURSING

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs)

(2014) Suzanne E. Wardell et al.   STEROIDS

Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease

(2013) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology

(2013) E. R. Nelson et al.   SCIENCE

Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden

(2012) G Frisk et al.   BRITISH JOURNAL OF CANCER

Research Resource: Transcriptional Profiling in a Cellular Model of Breast Cancer Reveals Functional and Mechanistic Differences Between Clinically Relevant SERM and Between SERM/Estrogen Complexes

(2012) Suzanne E. Wardell et al.   MOLECULAR ENDOCRINOLOGY

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy

(2011) Suzanne E. Wardell et al.   BIOCHEMICAL PHARMACOLOGY

An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis

(2011) Barry S. Komm et al.   MATURITAS

The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor   and Cyclin D1

(2011) J. S. Lewis-Wambi et al.   MOLECULAR PHARMACOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY